Please check your internet connection and try again.
**Drug:** TUSQ (Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd - *It appears the drug name is truncated or encoded. Assuming this refers to TUSQ, a combination product.*
## Overview
TUSQ is a combination medication containing hydrocodone bitartrate (an opioid analgesic and antitussive) and guaifenesin (an expectorant).
## Primary Indications
* Symptomatic relief of cough associated with conditions requiring a decrease in the frequency and intensity of coughing.
* Aids in loosening mucus in the airways.
## Adult Dosing
* **Typical Dose:** 10 mL orally every 4 to 6 hours as needed.
* **Maximum Dose:** Not to exceed 40 mL in 24 hours.
## Pediatric Dosing
* **Children 6 to 12 years:** 5 mL orally every 4 to 6 hours as needed.
* **Maximum Dose (6-12 years):** Not to exceed 20 mL in 24 hours.
* **Children under 6 years:** Safety and efficacy have not been established. Dosing should be determined by a healthcare provider based on clinical assessment.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Dose adjustments may be necessary based on individual response and renal function.
* **Hepatic Impairment:** Use with caution. Dose adjustments may be necessary based on individual response and hepatic function.
## Contraindications
* Hypersensitivity to hydrocodone, guaifenesin, or any component of the formulation.
* Significant respiratory depression.
* Acute or severe asthma or other obstructive airway disease.
* Gastrointestinal obstruction or paralytic ileus.
* Use in children younger than 6 years of age.
## Adverse Effects
* **Common:** Drowsiness, dizziness, constipation, nausea, vomiting, lightheadedness, sedation.
* **Serious:** Respiratory depression, opioid dependence, abuse potential, severe allergic reactions (anaphylaxis), CNS depression.
## Key Drug Interactions
* **CNS Depressants (e.g., benzodiazepines, alcohol, sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** Potentially exaggerated effects of hydrocodone; avoid concurrent use or within 14 days of discontinuing MAO inhibitors.
* **Other Opioid Analgesics:** Increased risk of adverse effects, particularly respiratory depression.
* **Anticholinergics:** Increased risk of urinary retention and severe constipation.
## Monitoring
* Respiratory rate and depth.
* Level of consciousness and sedation.
* Bowel function (for constipation).
* Signs of abuse or dependence.
* Pain and cough severity.
## Clinical Pearls
* Due to the hydrocodone component, this medication has a potential for abuse and dependence. Prescribe and dispense with caution.
* Drowsiness is a common side effect; advise patients to avoid driving or operating heavy machinery until they know how this medication affects them.
* Encourage adequate fluid intake to help loosen mucus.
* Consider alternative therapies for chronic cough or cough associated with conditions where suppression is not desired.
* The need for regular dosing versus PRN dosing should be assessed based on the patient's cough severity and frequency.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always verify current prescribing information, including dosing, contraindications, and safety warnings, with the official drug product labeling and consult with a qualified healthcare provider before making any treatment decisions.*
